
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Hldgs is well-positioned to capitalize on the growing demand for innovative treatments for respiratory diseases, with promising clinical data and a strong pipeline of potential therapies. However, investors should carefully monitor the progress and success of clinical trials and keep in mind the risks associated with biopharmaceutical development. Overall, the company's focus on addressing unmet needs in the respiratory market and its potential for global expansion make it a promising investment opportunity for those with a long-term outlook.
Bears say
Connect Biopharma Hldgs is a clinical-stage biotech company developing treatments for lung indications with its lead program rademikibart, an IL-4Rα inhibitor currently progressing through Phase 2 development for acute COPD and asthma. While rademikibart shows promise in its faster onset compared to Dupilumab, which is only approved for chronic use, the success of Dupilumab may be difficult to compete with given its greater clinical evidence and established relationship with Sanofi and Regeneron. Additionally, Dupilumab has been associated with risks of hyper-eosinophilia which could complicate treatment, making it a potential challenge for rademikibart to compete.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares